Ali Siedor is an associate in Goodwin’s Intellectual Property Litigation practice and a member of the Life Sciences Disputes group. She focuses on patent litigation and strategic IP counseling for pharmaceutical and biotechnology companies, with experience spanning Hatch-Waxman and complex life sciences disputes across district courts, arbitrations, ITC investigations, and post-grant proceedings. Drawing on her clinical background as a registered nurse, Ali brings a practical understanding of medical and scientific issues to matters involving drug products, biologics, and emerging therapeutics.
Experience
Ali’s experience includes all stages of litigation, including pre-suit analysis, fact and expert discovery, trial, post-trial proceedings, and strategic settlement resolutions. Representative matters include:
- Represented global generic pharmaceutical company in Hatch-Waxman litigation involving a generic injectable for post-surgical pain relief. After a bench trial, the United States District Court for the District of New Jersey found the asserted patents invalid.
- Represented global generic pharmaceutical company in the District of New Jersey in multiple consolidated, parallel Hatch-Waxman litigations involving a generic antidepressant drug and over 100 Orange Book-listed patents. The matter was resolved with a mutually acceptable settlement.
- Represented university in a patent infringement and breach of contract case involving muscle-derived stem cells. The matter was resolved with a mutually acceptable settlement just prior to trial.
- Represented global generic pharmaceutical company in Hatch-Waxman litigation involving a generic pulmonary drug. After a bench trial, the United States District Court for the District of Delaware found the asserted patents either noninfringed or invalid.
- Represented a biotechnology research company in an ICC arbitration concerning the company’s right to milestone and royalty payments for a peptide therapeutic under a licensing and collaboration agreement. The matter was resolved with a mutually acceptable settlement on the eve of arbitration.
- Represented global pharmaceutical company in an ITC investigation involving a complex injectable therapeutic.
Pro bono
Ali is actively involved in Goodwin’s pro bono practice. She currently serves as a member of the firm’s leadership team in partnership with GLAD’s Transgender ID Project and has worked on a variety of immigration-related matters, including Humanitarian Parole with a successful family reunification and a successful SIJS petition leading to a grant of permanent resident status for an unaccompanied minor. Ali has also achieved successful outcomes in several social security disability claims and in a VA disability claim. While a summer associate at Goodwin, Ali worked on a clemency petition for a federal inmate serving a life sentence for a nonviolent drug offense. The petition was approved, and the client’s life sentence was commuted by President Obama.Professional Experience
Prior to and during law school, Ali worked as a registered nurse on a neurology, neurosurgery, and trauma floor.
While in law school, Ali externed at the Children’s Law Center as a guardian ad litem for children involved in custody disputes, volunteered with Greater Hartford Legal Aid, and served as the articles and commentary editor for the Connecticut Law Review.
Credentials
Education
JD2017
University of Connecticut School of Law
BSN2012
University of Delaware
Admissions
Bars
- District of Columbia
- New York
- Washington
Courts
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the Southern District of New York
Recognition & Awards
Ali graduated with high honors from the University of Connecticut School of Law, and was a Pro Bono Honoree with over 100 hours of pro bono legal service.
Publications
- Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” Thomson Reuters, January 2024
- Special Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” Thomson Reuters, December 2022
- Special Contributor, "Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed.," Thomson Reuters, January 2021
- Co-Author, “Introduction to Biosimilars and Labeling Issues,” For the Defense, September 2020
- Co-Author, “Pandemic Spotlights Opportunistic Product Health Claims,” Law360, March 2020
- Co-Author, “Guide to Biosimilars Litigation and Regulation in the U.S.,” Thomson Reuters, November 2019
- Co-Author, “The 2018 Biosimilar Litigation Landscape: A Primer,” BioPharmadive, December 2017
Ali is also an editor of the firm’s biosimilars blog, Big Molecule Watch, which provides resources and observations through Goodwin’s active watch of legal, business and regulatory developments related to biologics, biosimilars, and the Biologics Price Competition and Innovation Act (BPCIA).